# Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma

> **NCT00112463** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Adult Alveolar Soft-part Sarcoma
- Adult Angiosarcoma
- Adult Epithelioid Sarcoma
- Adult Extraskeletal Chondrosarcoma
- Adult Extraskeletal Osteosarcoma
- Adult Fibrosarcoma
- Adult Leiomyosarcoma
- Adult Liposarcoma
- Adult Malignant Fibrous Histiocytoma
- Adult Malignant Hemangiopericytoma
- Adult Malignant Mesenchymoma
- Adult Neurofibrosarcoma
- Adult Rhabdomyosarcoma
- Adult Synovial Sarcoma
- Gastrointestinal Stromal Tumor
- Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Stage III Adult Soft Tissue Sarcoma
- Stage IV Adult Soft Tissue Sarcoma

## Interventions

- **DRUG:** romidepsin

## Key facts

- **NCT ID:** NCT00112463
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01-07
- **Primary completion:** 2008-10-23
- **Final completion:** 2008-10-23
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00112463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00112463, "Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00112463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*